Radial Approach to Coronary Angiography and PCI Cath Conference February 10, 2011 Darryn Appleton.

Slides:



Advertisements
Similar presentations
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Advertisements

Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48 Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin.
The Radial Approach to Percutaneous Coronary Intervention Is Associated With a Lower Risk for Complications Regardless of Radial Procedure Volume: A Report.
Predictors of Major Vascular Access Site Complications in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Safety and Effectiveness of Bivalirudin in NSTE ACS by duration of the upstream infusion in the ACUITY trial: Implications for ED and upstream management.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Pharmacological strategies to reduce periprocedural bleeding
ACS and Thrombosis in the Emergency Setting
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
BLEEDING AND ACUTE CORONARY SYNDROMES Cardiac Catherization Conference Syed Raza MD Cardiology Fellow VCU Medical Center 06/02/2011.
OASIS 5 Access AHA 2006 Martial Hamon, Shamir Mehta, Gabriel Steg, David Faxon, Prafulla Kerkar, Hans-Jürgen Rupprecht, Jean-Francois Tanguay, Rizwan Afzal,
ICE Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Sunil V. Rao MD The Duke Clinical Research Institute The Durham VA Medical Center Duke University Medical Center Transradial PCI in Octogenarians: Caveats,
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Latina, Italy Radial access for coronary.
Trans-Radial Approach for STEMI Evolution of TRA in single center Rationale behind increased TRA use Progression to use in STEMI Data analysis of STEMI.
RADIAL OR BUST The only choice for vascular access
Radial versus Femoral Approach for Percutaneous Coronary Procedures: A Meta-analysis of Randomized Trials 6th EUROPEAN WORKSHOP ON TRANSRADIAL APPROACH.
TRI vs TFI in STEMI Shenyang Northern Hospital Wang Shouli Han Yalin.
Switch Switch Safety and Efficacy of Crossover (Switch) from UFH/Enox to Bivalirudin: Results from ACUITY Dr. Harvey White Green Lane Cardiovascular Service.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.
Baseline Characteristics Current or Former Smoker Diabetic Hypertension 25.7 Prior MI Prior Heart Failure.
Alternative Approach Trans-Ulnar Approach Feasibility of Percutaneous Coronary Intervention Via Transulnar Artery Approach in Selected Patients with Coronary.
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.
Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
Disclosure Statement of Financial Interest
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Bivalirudin: Myths vs Reality? Dr Reman McDonagh Nycomed UK Ltd Conflict of Interest: Senior Manager working for Nycomed UK Ltd.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
AntiThrombotic Therapy in the Cath Lab: Preliminary Results from the NICE Trials Cindy L. Grines, M.D. William Beaumont Hospital Royal Oak, Michigan Cindy.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Impact of Anticoagulation Regimens on Sheath Management and Bleeding in Patients Undergoing Elective Percutaneous Coronary Intervention in the STEEPLE.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Heparin Should be the First-line Therapy for Patients with ACS/AMI
How To Minimize Bleeding In The Cath Lab
Management of Patients on Chronic Oral Anticoagulant Therapy
Pros and Cons of Radial Access
What´s New in the Literature on Transradial Intervention
Women, Bleeding, and Coronary Intervention
Why Radial Access Should be the Default for Women undergoing PCI?
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
Antiplatelet Therapy For STEMI: The Case for Cangrelor
Radial vs Femoral Access in ACS Patients
Sunil V. Rao MD The Duke Clinical Research Center
How to Minimize Bleeding in STEMI Patients Outline: -Know about bleeding -Think about consequences of bleeding -Identify bleeding risk factors -Maximize.
The HORIZONS-AMI Trial
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
% Heparin + GPI IIb/IIIa Bivalirudin +
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
Erasmus MC, Thoraxcenter
Implications of Preoperative Thienopyridine Use
Maintenance of Long-Term Clinical Benefit with
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

Radial Approach to Coronary Angiography and PCI Cath Conference February 10, 2011 Darryn Appleton

Outline Historical perspective and current trends Rationale for the radial approach ◦ Bleeding complications Comparison of radial and femoral access Radial approach in STEMI cases Some radial specific issues Educational resources and training

Historical Perspective 1948: First attempted transradial coronary angiogram using radial cut-down 8-10 F catheters: too big for the radial artery! 1989: Campeau reported first 100 cases of percutaneous transradial coronary angiogram 1993: First transradial coronary angioplasty with stent implantation performed Performed using 6F guide catheter

Current Trends Rao et al, JACC Interventions 2008; 1:

Current Trends Rao et al, JACC Interventions 2008; 1:

Rationale for use of TRA Advantages: ◦ Reduced risk of major bleeding ◦ Improved patient comfort and convenience ◦ Immediate ambulation ◦ Reduced inpatient time and cost, faster turnover of beds

Bleeding Complications Advances in antiplatelet and anticoagulant therapies in patients with ACS undergoing PCI have reduced ischemic events and improved overall outcomes Bleeding complications remain a relatively infrequent but significant problem Bleeding associated with increase risk of mortality, recurrent MI and stroke

Meta-analysis of Bleeding in ACS Data from 10 studies up to March 2007 included in a meta-analysis of studies in ACS where incidence of major bleeding and outcomes was published Hamon et al, EuroIntervention 2007; 3:

Major Femoral Bleeding Post-PCI Mayo clinic PCI database Changes in type, intensity and duration of anticoagulation protocols over time Group Group Group n Sheath size (F)8.2 ± ± ± 0.8 GP Iib/IIIa use27 (1%)2536 (41%)5328 (58%) Peak ACT405 ± ± ± 61 Heparin post procedure 1995 (80%)2215 (36%)2456 (27%) Doyle et al, JACC Interventions 2008 ; 1: 202-9

Major Femoral Bleeding Post-PCI Doyle et al, JACC Interventions 2008 ; 1: 202-9

OASIS-5: Fondaparinux Comparison of Fondaparinux vs Enoxaparin in patients with ACS Primary efficacy outcome: ◦ D/MI/Isch at 9 days: Non-inferiority Primary safety outcome: ◦ Major bleeding at 9 days: Superiority Yusuf et al, NEJM 2006; 354:

OASIS-5: Fondaparinux Regardless of Treatment Arm, those who suffered a major bleeding event had worse outcomes at 30 days: ◦ Increased risk of death (13.2% vs 2.8%) ◦ Increased risk of MI (11.9% vs 3.6%) ◦ Increased risk of stroke (3.5% vs 0.7%) Yusuf et al, NEJM 2006; 354:

ACUITY: Bivalirudin Bivalirudin (Angiomax) is a direct thrombin inhibitor ACUITY enrolled patients with moderate to high risk ACS and randomized pts to three arms: ◦ Heparin + GP IIb/IIIa Inhibitor ◦ Bivalirudin + GP IIb/IIIa Inhibitor ◦ Bivalirudin alone Stone et al, NEJM 2006;355:

Bivalirudin Alone

Vascular Closure Devices in ACUITY 37% of patients in ACUITY trial received a VCD Risk of major access site bleed lower with VCD (2.5% v 3.3%, p = 0.04) Rates were lowest in those on Bivalirudin monotherapy treated with VCD Logistic regression showed both VCD and Bivalirudin were independent predictors of freedom of major bleeding Sanborn et al, CCI 2010; 3: 57-62

Choice of Access Site in ACUITY Femoral site chosen in 93.8% Radial site chosen in 6.2% Subgroup analysis with some important differences in baseline characteristics: ◦ Femoral approach more commonly used in:  Older patients  Females  Established CAD  Enrolled in the US Hamon, EuroIntervention 2009; 1:

Choice of Access Site in ACUITY No difference in composite outcome of death / MI / ischemia at 30 days or at 1 year Bleeding: RadialFemoralP-value Access site bleeding0.9%2.1%0.009 TIMI non-CABG major bleeding 1.0%1.5%0.37 Non-CABG major bleeding 3.0%4.8%0.03 Hamon, EuroIntervention 2009; 1:

MORTAL Study British Columbia Cardiac Registry (similar to NCDR) used to evaluate patients who had undergone PCI from Cross-referenced with Central Transfusion Registry to identify patients transfused within 10 days of PCI Objective: ◦ To determine association of arterial access site (radial vs femoral) with transfusion and mortality Chase et al, Heart 2008; 94:

MORTAL Study Baseline characteristics: multiple variables with statistically significant differences VariableRadial N = 7,972 Femoral N = 30,900 P-value Elective32.4%26.3%< 0.01 Urgent55.3%62.4%< 0.01 Dialysis0.7%1.8%< 0.01 Prior MI25.5%34.1%< 0.01 Prior CABG6.9%13.5%< 0.01 **Liver/GI comorbidities 2.4%6.9%< 0.01 **Malignancy2.3%7.2%< 0.01

Chase et al, Heart 2008; 94:

MORTAL Study - Transfusion Odds Ratios (adjusted for baseline characteristics) for mortality related to receiving transfusion vs no transfusion: ◦ 30 day: 4.01 (95% CI 3.08 to 5.22) ◦ 1 year: 3.58 (95% CI 2.94 to 4.36) Propensity Score Matching confirmed higher risk of 30d and 1year mortality if transfused Chase et al, Heart 2008; 94:

MORTAL Study – Access Site Odds Ratios (adjusted for baseline characteristics) for receiving a transfusion based on Radial vs Femoral access: ◦ 0.59 (95% CI 0.48 to 0.73), p < Adjusted OR for mortality: TRA v TFA ◦ 30 day: 0.71 (95% CI 0.61 to 0.82) p < ◦ 1 year: 0.83 (95% CI 0.71 to 0.98) P < If only non-transfused procedures analyzed, difference in mortality non-significant ◦ Supports hypothesis that mortality difference closely linked with need for transfusion Chase et al, Heart 2008; 94:

Mortality & Bleeding / Transfusion Doyle et al, JACC 2009; 53:

RIVIERA Study Multinational prospective observation study to determine predictors of adverse outcomes following PCI 7962 patients from 23 countries Both elective (92%) and primary PCI (8%) Radial approach: 841 pts (10.6%) Femoral approach: 7062 pts (89.2%) Montelescot et al, Int J Card 2008; 129(3):

RIVIERA Study: Death / MI Montelescot et al, Int J Card 2008; 129(3):

RIVIERA Study: Bleeding Montelescot et al, Int J Card 2008; 129(3):

Mechanisms for Increased Mortality

Why all this talk about bleeding? Bleeding complications are a big deal Needing a transfusion after cath is a marker of high risk – strongly (perhaps even causally) related to adverse events Efforts to further reduce risk of bleeding and reduce the chance of needing a transfusion are of utmost importance

Meta-analysis Radial vs Femoral 12 RCTs included spanning evaluating Coronary Angiography and/or PCI from TR vs TF approach Total of 3224 pts ◦ 1668 Transradial ◦ 1556 Transfemoral 7 studies - Diagnostic only 5 studies – PCI: of these 2 in ACS/AMI Agostoni et al, JACC 2004; 44:

Meta-analysis - MACE Agostoni et al, JACC 2004; 44:

Meta-analysis – Entry Site Complications Agostoni et al, JACC 2004; 44:

Meta-analysis – Procedural Failure Agostoni et al, JACC 2004; 44:

Meta-analysis: Secondary Endpoints Significant heterogeneity ◦ Fluoroscopy time shorter for Femoral  TFA – 7.8 min vs TRA – 8.9 min  (Diff: 1.05, 95% CI diff: 0.51 to 1.60, p < 0.001) ◦ Mean hospital stay shorter for Radial  TFA – 2.4 days vs TRA – 1.8 days  (Diff: 0.55, 95% CI diff: 0.29 to 0.82, p < 0.001) ◦ Total hospital charge lower for Radial Agostoni et al, JACC 2004; 44:

Meta-analysis 2: – Radial vs Femoral 23 studies included spanning 1993 – 2007 Major Bleeding: ◦ Radial: 0.5% (13 / 2390 pts) ◦ Femoral: 2.3% (48 / 2068 pts) OR: 0.27 (95% CI 0.16 – 0.45, p < 0.001) Trend towards reduced composite of death / MI / stroke  OR: 0.71 (95% CI 0.49 – 1.01, p = 0.058) Trend towards reduced mortality  OR 0.74 (95% CI 0.42 – 1.30, p = 0.29) Jolly et al, Am Heart J 2009; 157: )

Radial PCI in STEMI Single center longitudinal cohort study 530 patients with STEMI undergoing primary PCI < 12hrs enrolled in registry Access: chosen at discretion of operator Default access = Radial, with Femoral access used if unfavorable Allen test or h/o CABG Baseline characteristics: ◦ Radial group more likely to be older, male, higher BMI, less likely to have prior MI Azmendi et al, Am J Card 2010; 106(2):

Radial PCI in STEMI - Survival Azmendi et al, Am J Card 2010; 106(2):

Radial PCI in STEMI - MACE Azmendi et al, Am J Card 2010; 106(2):

Radial PCI in STEMI - MACE Azmendi et al, Am J Card 2010; 106(2):

STEMI Case at VCU 60 yo M presented to the VAMC with chest pain ◦ Initial CE and EKG negative for evidence of ischemia / AMI ◦ Ongoing chest pain: subsequent EKG showed STE in V2-V4 ◦ Given ASA, Plavix and TNK ◦ Transferred to VCUHS for rescue PCI ◦ Radial access chosen

Video 4

Video 7

Video 13

LAD Intervention: EBU4 6F Guide Driver RX 3.5 x 24mm stent

Video 15

RCA Intervention: Barbeau 6F Guide Driver RX 4.0 x 24mm stent

VCU Experience 2010 Overall cases ◦ Diagnostic (67.5%) ◦ PCI (32.5%) Radial cases – 216 (6.8%) Access Site Complication Rate: ◦ Radial: 0/216 ◦ Femoral: 46/3112 (1.5%)  3 Retroperitoneal Bleeds  9 Hematomas  10 Transfusions

VCU Experience 2010 VCU’s most prolific Radialist in 2010: ◦ Kapil Lotun:  57 Trans-radial PCI  132 Trans-radial Diagnostic

Door-to-Balloon time Single-center observational study PCI operators ◦ 1 preferred TF, 1 preferred TR, 2 no preference – all trained in both 240 consecutive STEMI cases 205 undergoing successful PCI ◦ 124 trans-radial ◦ 116 trans-femoral Weaver et al, CCI 2010; 75:

Door-to-Balloon time Weaver et al, CCI 2010; 75:

Door-to-Balloon time Weaver et al, CCI 2010; 75:

Radiation Exposure Study performed in Germany where one experienced operator (>1500 radial cases) performed coronary angiography ± PCI Pts randomized to TR or TF approach Radiation dosimeter used to measure operator exposure in µSv Patient radiation dose measured in terms of dose-area product (Gy.cm 2 ) and fluoroscopy time Lange et al, CCI 2006; 67: 12-16

Radiation Exposure Potential for increased radiation exposure both to patient and operator Close attention to techniques and precautions for minimizing exposure needed Lange et al, CCI 2006; 67: 12-16

Radial Artery Occlusion Incidence post TRA: ◦ 5% based on clinical diagnosis ◦ 9% based on ultrasonography Risk of RAO independently associated with ◦ sheath/artery ratio > 1 ◦ Lack of peri-procedural anticoagulation Hand ischemia rare, but RAO has implications for: ◦ access for subsequent coronary angiography ◦ future use of radial artery as graft for CABG or fistula for HD

Patent Hemostasis Reduces RAO PROPHET: 436 patients randomized to: ◦ Conventional Hemostasis  Hemoband applied with immediate sheath removal  Band removed after 2 hrs  Radial patency was checked using Barbeau’s test but pressure not adjusted (43% were occlusive) ◦ Patent Hemostasis  Pulse oximeter sensor applied to index finger  Ulnar artery occluded with manual pressure  Hemoband applied as above, loosened until signal returned  confirms radial patent  Band removed after 2 hrs as above Pancholy et al, CCI 2008; 2:

Patent Hemostasis Reduces RAO Radial patency checked by Barbeau’s test at 24hrs and 1 month No bleeding complications in either group 3.6% in Patent Hemostasis group required manual pressure application – unable to achieve hemostasis with patent radial Pancholy et al, CCI 2008; 2:

Radial Artery as Graft After TRA? Retrospective cohort study of pts undergoing CABG ◦ 22 in Group 1 – TRA ◦ 45 in Group 2 – no prior TRA Post-op angiographic assessment of graft patency performed at 1 month Kamiya et al, Ann Thor Surg 2003; 76:

Learning Curve Trans-radial approach perceived as more difficult to learn than trans-femoral ◦ Small sized vessel ◦ Prone to spasm ◦ Higher percentage of anatomic variation ◦ Can be difficult to transverse the subclavian and aortic arch

Learning Curve Early studies report failure rates of: ◦ First 50 cases: around 10% ◦ First 500 cases: 3-4% ◦ After 1000 cases: approx 1% Spaulding et al, Cath Cardiovasc Diagnosis 1996; 39:

CATHETERS

Catheters

Educational Resources & Training ◦ Has a calendar of training courses

Video html html

Educational Resources & Training

Summary Trans-radial PCI is a safe and effective alternative to the trans-femoral approach, both for elective and emergent cases Associated with reduction in bleeding complications and need for transfusion High success rates after initial learning curve period

Acknowledgements Special thanks to Dr Kapil Lotun